Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1/2 7Phase 1 5Phase EARLY_PHASE1 1

Status

Completed 5Terminated 2Recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 4NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 2Other solid neoplasm 1CNS 1

Conditions

Neoplasms 2Glioma 1Glioblastoma 1Brain Neoplasms 1Advanced Solid Tumors 1Advanced Cancer 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Completed × relatlimab × Clear all
NCT02966548 2025-02-17

Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors

Bristol-Myers Squibb

Phase 1 Completed
35 enrolled
Tumor-Agnostic

Neoplasms

NCT03493932 2024-07-24

Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
21 enrolled 9 charts
CNS

Brain Neoplasms, Glioblastoma, Glioma

NCT05498480 2024-02-20

RELATIVITY-111

Bristol-Myers Squibb

Phase 1 Completed
6 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT04112498 2023-04-06

A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab

Bristol-Myers Squibb

Phase 1 Completed
24 enrolled
Tumor-Agnostic

Neoplasms

NCT03335540 2022-09-26

ADVISE

Bristol-Myers Squibb

Phase 1 Completed
20 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡